Nothing Special   »   [go: up one dir, main page]

Valenzuela et al., 2013 - Google Patents

Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury

Valenzuela et al., 2013

View HTML
Document ID
6262090506559909789
Author
Valenzuela N
Reed E
Publication year
Publication venue
Transplantation Immunology: Methods and Protocols

External Links

Snippet

Until recently, allograft rejection was thought to be mediated primarily by alloreactive T cells. Consequently, immunosuppressive approaches focused on inhibition of T cell activation. While short-term graft survival has significantly improved and rejection rates have dropped …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Similar Documents

Publication Publication Date Title
Valenzuela et al. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury
Colvin et al. Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association
Valenzuela et al. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms
Butler et al. Not all antibodies are created equal: factors that influence antibody mediated rejection
Reinsmoen et al. Increased negative impact of donor HLA-specific together with non-HLA–specific antibodies on graft outcome
Moreau et al. Effector mechanisms of rejection
Tait et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation
Zhang et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction
Reinsmoen et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients
Jaramillo et al. DEVELOPMENT OF ELISA-DETECTED ANTI-HLA ANTIBODIES PRECEDES THE DEVELOPMENT OF BRONCHIOLITIS OBLITERANS SYNDROME AND CORRELATES WITH PROGRESSIVE DECLINE IN PULMONARY FUNCTION AFTER LUNG TRANSPLANTATION1
Cantarovich et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome
Zhang et al. Non-MHC antigenic targets of the humoral immune response in transplantation
Bentall et al. Antibody‐mediated rejection despite inhibition of terminal complement
Dalmasso et al. Resistance against the membrane attack complex of complement induced in porcine endothelial cells with a Galα (1–3) Gal binding lectin: Up-regulation of CD59 expression
Valenzuela et al. Antibody subclass repertoire and graft outcome following solid organ transplantation
Chih et al. Antibody‐mediated rejection: an evolving entity in heart transplantation
Lobo et al. Natural IgM anti-leukocyte autoantibodies attenuate excess inflammation mediated by innate and adaptive immune mechanisms involving Th-17
Smith et al. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates
Kim et al. Therapies for chronic allograft rejection
Gao et al. Evidence to support a contribution of polyreactive antibodies to HLA serum reactivity
Ko et al. Endothelial CD200 is heterogeneously distributed, regulated and involved in immune cell–endothelium interactions
Lee et al. Investigation of serum angiotensin II type 1 receptor antibodies at the time of renal allograft rejection
Higgins et al. Antibody-incompatible kidney transplantation in 2015 and beyond
Lammerts et al. Antigen and cell-based assays for the detection of non-HLA antibodies
Salvadori et al. Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy